EGFR and non-small cell lung carcinoma: Some non-small-cell lung cancer (NSCLC) patients experience acquired resistance due to circumstances that can interfere with EGFR signalling, such as the upregulation of other RTKs such as MET, the downstream activation of specific pathway elements or phenotypic and histological changes [39].